^
ALK R1209Q
Colon Cancer
crizotinib + pazopanib
Sensitive
:
C3
Onco Targets Ther - 6d
HER-2 positive
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
Lancet Oncol - 1wk
No biomarker
CRC
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
Biocon Press Release - 2wk
dMMR/MSI-H + TMB-L
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 2wk
PTEN mutation + MSI-H/dMMR
CRC
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 2wk
MSI-H/dMMR
CRC
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600E
CRC
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive
:
A1
No biomarker
Colon Cancer
capecitabine
Sensitive
:
A1
No biomarker
Rectal Cancer
FOLFIRI
Sensitive
:
A1
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive
:
A1
No biomarker
CRC
bevacizumab
Sensitive
:
A1
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant
:
A1
No biomarker
CRC
trifluridine/tipiracil
Sensitive
:
A1
No biomarker
CRC
ziv-aflibercept IV
Sensitive
:
A1
No biomarker
CRC
capecitabine
Sensitive
:
A1
EGFR expression
CRC
cetuximab
Sensitive
:
A1
KRAS Q61
CRC
cetuximab
Resistant
:
A1
No biomarker
CRC
ramucirumab
Sensitive
:
A1
No biomarker
CRC
panitumumab
Sensitive
:
A1
KRAS A146
CRC
cetuximab
Resistant
:
A1
No biomarker
Rectal Cancer
irinotecan
Sensitive
:
A1
No biomarker
Colon Cancer
irinotecan
Sensitive
:
A1
KRAS G13
CRC
cetuximab
Resistant
:
A1
KRAS G12
CRC
cetuximab
Resistant
:
A1
No biomarker
CRC
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our